Table 1.
Baseline characteristics of study population (n = 759)
| Total (n = 759) | Culture-negative (n = 238) | Culture status unknown/ culture not performed (n = 228) | Culture-positive (n = 293) | |
|---|---|---|---|---|
| Characteristic | n (%) | n (%) | n (%) | n (%) |
| Age, years, median [IQR] | 35 [30–43] | 36 [29–43] | 36 [30–43] | 35 [30–43] |
| Male sex | 581 (77) | 194 (82) | 160 (70) | 227 (77) |
| Study site | ||||
| Argentina | 61 (8) | 13 (5) | 9 (4) | 39 (13) |
| Brazil | 237 (31) | 48 (20) | 53 (23) | 136 (46) |
| Chile | 44 (6) | 19 (8) | 16 (7) | 9 (3) |
| Honduras | 26 (3) | 11 (5) | 11 (5) | 4 (1) |
| Mexico | 27 (4) | 10 (4) | 0 (0) | 17 (6) |
| Peru | 364 (48) | 137 (58) | 139 (61) | 88 (30) |
| Site of TB disease | ||||
| Pulmonary only | 356 (47) | 117 (49) | 98 (43) | 141 (48) |
| Any extra-pulmonary | 403 (53) | 121 (51) | 130 (57) | 152 (52) |
| CD4 at TB diagnosis, median [IQR] | 96 [40–228] | 87 [37–223] | 100 [41–222] | 97 [45–241] |
| Missing CD4 at TB diagnosis | 149 (20) | 57 (24) | 36 (16) | 56 (19) |
| AFB smear status | ||||
| Negative | 347 (46) | 173 (73) | 70 (31) | 104 (35) |
| Unknown/not performed | 116 (15) | 7 (3) | 97 (43) | 12 (4) |
| Positive | 296 (39) | 58 (24) | 61 (27) | 177 (60) |
| TB diagnosis relative to ART | ||||
| Never on ART | 38 (5) | 3 (1) | 20 (9) | 15(5) |
| ART concurrent with anti-tuberculosis treatment | 636 (84) | 190 (80) | 198 (87) | 248 (85) |
| ART before or after anti-tuberculosis treatment | 85 (11) | 45 (19) | 10 (4) | 30 (10) |
| TB diagnosis relative to ART | ||||
| Not on ART at TB diagnosis | 570 (75) | 173 (73) | 159 (70) | 238 (81) |
| On ART at TB diagnosis | 189 (25) | 65 (27) | 69 (30) | 55 (19) |
IQR = interquartile range; TB = tuberculosis; AFB = acid-fast bacilli; ART =antiretroviral therapy.